%0 Journal Article
%T Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review.
%A Mandala E
%A Lafara K
%A Kokkinovasilis D
%A Kalafatis I
%A Koukoulitsa V
%A Katodritou E
%A Lafaras C
%J Life (Basel)
%V 14
%N 4
%D 2024 Apr 18
%M 38672794
%F 3.251
%R 10.3390/life14040524
%X Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity's definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and/or subclinical myocardial dysfunction and electrical instability. Moreover, the most common cardiotoxic profiles of the main drugs and/or therapeutic interventions in patients with hematological malignancies are described thoroughly.